Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A31
- Development stage
- Preclinical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A31 is a novel small molecule tyrosine kinase inhibitor (TKI) designed to target and inhibit the constitutive phosphorylation of fibroblast growth factor receptor 3 (FGFR3). This inhibition aims to restore normal chondrocyte differentiation and promote bone growth, addressing the underlying pathology of conditions caused by activating FGFR3 mutations, such as achondroplasia and other skeletal dysplasias. The drug has shown promise in restoring the size of embryonic dwarf femurs and normalizing cell cycle regulators in Fgfr3(Y367C/+) dwarf mice, suggesting its potential for treating FGFR3-related chondrodysplasias.
02
Targets
FGFR3 (Fibroblast growth factor receptor 3)
Beyond the preview
Go deeper on A31.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on A31.